Why the study?
Does aspirin alone or in combination with dipyridamole reduce the risk of vascular events in patients with prior stroke or TIA?
Does aspirin alone or in combination with dipyridamole reduce the risk of vascular events in patients with prior stroke or TIA?
The combination of dipyridamole and aspirin is more effective than aspirin alone for the secondary prevention of vascular events in patients with prior stroke or TIA.
Answers are grounded in this paper and cite their sources.
Supports aspirin-dipyridamole over aspirin alone for secondary prevention after stroke/TIA; confirms and extends prior trial evidence.
Publication of the results of the second European Stroke Prevention Study (ESPS-2) provided the incentive for an update of the meta-analyses of aspirin and dipyridamole in the secondary prevention of stroke. After review of published randomized trials of prolonged treatment with aspirin, dipyridamole, or their combination in patients with a history of stroke or transient ischemic attack (TIA), data on the occurrence of stroke, myocardial infarction, and vascular death were used to calculate overall relative risk reductions. The relative risk reduction for aspirin versus placebo was 13%. The same relative risk reduction was found in separate meta-analyses of trials with high (1,000-1,500 mg), medium (250-500 mg), and low (50-100 mg) doses of aspirin. Trials in which different doses were compared showed no difference in the occurrence of vascular events. The addition of dipyridamole to low-dose aspirin further reduced the risk for vascular events by 15%. We conclude from current trials that low-dose aspirin alone reduced the risk of vascular events in patients with prior stroke or TIA by 13%. There is no evidence of a dose-effect relationship. An additional reduction of the risk by 15% can be obtained by adding dipyridamole to aspirin. The overall evidence for the relative effects of the combination of dipyridamole and aspirin versus aspirin alone or placebo is highly consistent. The clinical evidence now favors the two agents in combination over aspirin alone.
No takes yet. Share an insight, caveat, or question.
Jan G.P. Tijssen (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: